A polyvalent DNA prime with matched polyvalent protein/GLA-SE boost regimen elicited the most robust and broad IgG and IgG3 V1V2 binding antibody and CD4+ T cell responses among 13 HIV vaccine trials

Zoe Moodie, Shuying Sue Li, Elena Giorgi, LaTonya D. Williams, One Dintwe, Lindsay N. Carpp, Shiyu Chen, Kelly E. Seaton, Sheetal Sawant, Lu Zhang, Jack Heptinstall, Shuying Liu, Nicole Grunenberg, Frank Tomaka, Supachai Rerks‐Ngarm, Punnee Pitisuttithum, Sorachai Nitayaphan, Julie A. Ake, Sandhya Vasan, Giuseppe Pantaleo, Ian Frank, Lindsey R. Baden, Paul A. Goepfert, Michael C. Keefer, Mike Chirenje, Mina C. Hosseinipour, Kathryn Mngadi, Fatima Laher, Nigel Garrett, Linda‐Gail Bekker, Stephen De Rosa, Erica Andersen‐Nissen, James G. Kublin, Shan Lu, Peter B. Gilbert, Glenda Gray, Lawrence Corey, M. Juliana McElrath, Georgia D. TomarasEmerging 2025 · DOI

TL;DR

This study presents a large-scale comparison of 36 HIV vaccine regimens across 13 trials, identifying a polyvalent DNA prime with a matched polyvalent protein/GLA-SE boost (HVTN 124) as the most promising candidate. This regimen elicited the strongest and broadest antibody responses against key HIV envelope regions (V1V2) and robust CD4+ T-cell responses, suggesting it could be a strong contender for future efficacy trials.

What Problem Does This Paper Address?

Developing an effective HIV vaccine has been an immense challenge. Despite numerous trials, only one vaccine has shown modest efficacy, and many candidate vaccines have been poorly immunogenic. A key hurdle is the vast genetic diversity of HIV, requiring vaccines to elicit responses against a wide range of viral strains. Identifying which vaccine designs are most effective at generating the right kind of immune responses (immunogenicity) is crucial for guiding future development. This paper tackles the problem of systematically comparing the immunogenicity of a large number of diverse HIV vaccine regimens to pinpoint those with the most robust and broadly protective immune signatures.

Methods

The study performed a cross-protocol immunogenicity comparison of 36 HIV vaccine regimens from 13 different clinical trials. To achieve this, they utilized standardized trial designs, validated assays run in centralized laboratories, and harmonized immunogenicity endpoints. The primary assays used were:

  • Binding Antibody Multiplex Assay (BAMA): This assay measured IgG and IgG3 binding antibodies (bAbs) against various HIV-1 envelope (Env) V1V2 antigens. They specifically focused on "breadth scores," which quantify the geometric mean of responses to the top 3 heterologous V1V2 antigens, to account for variations in the number of antigens tested across trials.
  • Intracellular Cytokine Staining (ICS) Assay: This assay measured HIV-1-specific CD4+ and CD8+ T-cell responses to vaccine-matched peptide pools or global T-cell epitope pools. They focused on "Any Env" responses, representing the maximum response across all tested Env peptide pools.

Statistical comparisons, including Barnard's exact test for response rates and Wilcoxon rank-sum tests for response levels and breadth scores, were used to identify significant differences between regimens.

Datasets

The study analyzed data from 13 HIV vaccine clinical trials, encompassing 36 distinct vaccine regimens. These trials were conducted between 2003 and 2018 across nine countries, including Malawi, Mozambique, South Africa, Switzerland, Tanzania, Thailand, the United States, Zambia, and Zimbabwe. The participants were healthy adults aged 18-50 years who were HIV-negative at enrollment.

Key Insights and Ideas

  • The "Matched Prime-Boost" Advantage: The HVTN 124 regimen, which used a polyvalent DNA prime followed by a matched polyvalent protein/GLA-SE boost, demonstrated a significant advantage. The matching of Env immunogens between the prime and boost likely contributed to its superior performance.
  • Beyond Just Antibodies: While antibody responses are critical, the study also highlighted the importance of CD4+ T-cell responses. The HVTN 124 regimen excelled in eliciting both robust antibody and CD4+ T-cell responses, suggesting a more comprehensive immune activation.
  • GLA-SE Adjuvant Potential: The inclusion of the GLA-SE adjuvant in the HVTN 124 protein boost regimen appears to have contributed to the strong immune responses observed, warranting further investigation.
  • Standardization is Key: The success of this cross-protocol analysis was heavily reliant on standardized trial designs, validated assays, and harmonized endpoints, enabling a more objective comparison of immunogenicity across diverse studies.

Key Results

  • The HVTN 124 polyvalent DNA prime + polyvalent protein/GLA-SE boost regimen achieved the highest median IgG and IgG3 V1V2 binding antibody breadth scores, significantly outperforming most other regimens.
  • This HVTN 124 regimen also induced robust CD4+ T-cell responses to Env antigens, with a 100% response rate in some arms.
  • Compared to the RV144 and HVTN 097 regimens (which showed some efficacy), HVTN 124 induced significantly higher IgG and IgG3 breadth scores.
  • While other regimens showed promise, the HVTN 124 regimen consistently demonstrated superior breadth and magnitude of both antibody and CD4+ T-cell responses implicated in HIV vaccine protection.

Limitations and Future Work

  • T-cell Response Heterogeneity: A significant limitation is that most trials assessed T-cell responses to vaccine-matched peptide pools, while HVTN 124 and HVTN 106 used global peptide pools. This makes direct comparison of T-cell responses challenging, as matched pools are expected to yield higher responses.
  • Antigen Panel Limitations: The study notes that the antigen panels used for antibody assessment may not fully represent the vast diversity of circulating HIV strains, particularly for subtype B.
  • IgA Not Assessed Universally: Serum IgA antibodies, identified as a correlate of risk in the RV144 trial, were not measured in all studies and thus could not be included in the primary analysis.
  • Future Work: The authors strongly advocate for testing the HVTN 124 regimen in more advanced phase clinical trials. They also suggest that the findings will guide the future design of additional HIV vaccines, emphasizing the importance of polyvalent antigens and potentially novel adjuvants like GLA-SE. The field's ongoing focus on broadly neutralizing antibodies (bnAbs) is also mentioned as a key direction.

Summary updated

Abstract

Developing an effective HIV vaccine is a momentous challenge. An exceptionally wide range of candidate HIV vaccines have been tested, yet many were poorly immunogenic, and of the select few that advanced into efficacy trials, only one demonstrated any efficacy. Here we report the results of the largest-scale cross-protocol immunogenicity comparison to date: 13 HIV vaccine trials (including 36 vaccine regimens) conducted across nine countries worldwide, strengthened by standardized trial designs, validated assays in centralized laboratories, and harmonized immunogenicity endpoints - providing an objective approach to identify the HIV vaccine candidate(s) with the best immunogenicity. A polyvalent DNA prime + protein boost regimen (HVTN 124) including Env immunogens of four subtypes, matched between prime and boost, achieved the best anti-V1V2 antibody responses by a large margin and also induced high CD4+ T-cell responses - two key immune responses implicated in HIV vaccine protection. Our results provide strong support to test this promising HIV vaccine design in more advanced phase clinical trials and will also guide the future design of additional HIV vaccines.<b>Trial registration:</b> ClinicalTrials.gov identifier: NCT01799954..<b>Trial registration:</b> ClinicalTrials.gov identifier: NCT02109354..<b>Trial registration:</b> ClinicalTrials.gov identifier: NCT02404311..<b>Trial registration:</b> ClinicalTrials.gov identifier: NCT02207920..<b>Trial registration:</b> ClinicalTrials.gov identifier: NCT02296541..<b>Trial registration:</b> ClinicalTrials.gov identifier: NCT03284710..<b>Trial registration:</b> ClinicalTrials.gov identifier: NCT02915016..<b>Trial registration:</b> ClinicalTrials.gov identifier: NCT02997969..<b>Trial registration:</b> ClinicalTrials.gov identifier: NCT03122223..<b>Trial registration:</b> ClinicalTrials.gov identifier: NCT03409276..<b>Trial registration:</b> ClinicalTrials.gov identifier: NCT02968849..<b>Trial registration:</b> ClinicalTrials.gov identifier: NCT03060629..<b>Trial registration:</b> ClinicalTrials.gov identifier: NCT00223080..
BibTeX
@inproceedings{moodie2025polyvalent,
  author = {Zoe Moodie and Shuying Sue Li and Elena Giorgi and LaTonya D. Williams and One Dintwe and Lindsay N. Carpp and Shiyu Chen and Kelly E. Seaton and Sheetal Sawant and Lu Zhang and Jack Heptinstall and Shuying Liu and Nicole Grunenberg and Frank Tomaka and Supachai Rerks‐Ngarm and Punnee Pitisuttithum and Sorachai Nitayaphan and Julie A. Ake and Sandhya Vasan and Giuseppe Pantaleo and Ian Frank and Lindsey R. Baden and Paul A. Goepfert and Michael C. Keefer and Mike Chirenje and Mina C. Hosseinipour and Kathryn Mngadi and Fatima Laher and Nigel Garrett and Linda‐Gail Bekker and Stephen De Rosa and Erica Andersen‐Nissen and James G. Kublin and Shan Lu and Peter B. Gilbert and Glenda Gray and Lawrence Corey and M. Juliana McElrath and Georgia D. Tomaras},
  title = {{A polyvalent DNA prime with matched polyvalent protein/GLA-SE boost regimen elicited the most robust and broad IgG and IgG3 V1V2 binding antibody and CD4+ T cell responses among 13 HIV vaccine trials}},
  booktitle = {Emerging},
  year = {2025},
  doi = {10.1080/22221751.2025.2485317},
}
Figure